Arch Therapeutics Revenue and Competitors

Location

$20.9M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Arch Therapeutics's estimated annual revenue is currently $1.7M per year.(i)
  • Arch Therapeutics's estimated revenue per employee is $142,083
  • Arch Therapeutics's total funding is $20.9M.

Employee Data

  • Arch Therapeutics has 12 Employees.(i)
  • Arch Therapeutics grew their employee count by 20% last year.

Arch Therapeutics's People

NameTitleEmail/Phone
1
VP SalesReveal Email/Phone
2
SVP, Sales & MarketingReveal Email/Phone
3
Head QualityReveal Email/Phone
4
Chief Financial OfficerReveal Email/Phone
5
Project ManagerReveal Email/Phone
6
Chairman the Board Directors, President & CEOReveal Email/Phone
7
Senior Medical Science LiaisonReveal Email/Phone
8
Sales DirectorReveal Email/Phone
9
President and CEOReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M20%N/AN/A
#3
$5.1M336%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.4M353%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is Arch Therapeutics?

Arch Therapeutics, Inc. (OTCQB:ARTH) is a biotechnology company developing a novel approach to stop bleeding (hemostasis), control leaking (sealant) and manage wounds during surgery, trauma and interventional care. Arch is developing products based on an innovative self-assembling barrier technology platform with the goal of making care faster and safer for patients. Arch has received regulatory authorization to market AC5® Advanced Wound System and AC5® Topical Hemostat as medical devices in the United States and Europe, respectively. Arch's development stage product candidates include AC5-G™, AC5-V® and AC5® Surgical Hemostat, among others.1,2 1 AC5-G, AC5-V, and AC5 Surgical Hemostat are currently investigational devices limited by law to investigational use. 2 AC5, AC5-G, AC5-V and associated logos are trademarks and/or registered trademarks of Arch Therapeutics, Inc. and/or its subsidiaries.

keywords:N/A

$20.9M

Total Funding

12

Number of Employees

$1.7M

Revenue (est)

20%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Arch Therapeutics News

2022-04-13 - Renowned Wound Care Key Opinion Leaders Presented Arch ...

FRAMINGHAM, Mass., April 13, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and...

2022-03-30 - Arch Therapeutics' AC5® Advanced Wound System to be ...

(OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical devices, today announced...

2022-03-22 - Arch Therapeutics Partners with Centurion Therapeutics to ...

FRAMINGHAM, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1.2M12-69%N/A
#2
$1.9M1271%N/A
#3
$1.8M12N/AN/A
#4
$2M138%N/A
#5
$1.2M140%N/A